InvestorsHub Logo
Boards
News
Market Data
Markets
Discover
Discover
Subscribe Login/Register
S&P 500
5,567.19
(
1.06%
)
US TECH 100
19,828.00
(
0.95%
)
Dow Jones
39,375.87
(
0.17%
)
Brent Oil
86.09
(
-0.49%
)
Bitcoin
54,786.80
(
-1.90%
)
Post# of 252504
Next 10
Reply Private New
Public Reply Private Reply New Post
Keep Last Read
Keep Next 10 Report Keyboard Shortcuts
Next 10 Prev Next

DewDiligence

Send PM Follow Ignore
Followers 832
Posts 119984
Boards Moderated 17
Alias Born 09/05/2002

DewDiligence

Member Level

Re: DewDiligence post# 238735

Friday, 09/24/2021 3:57:07 PM

Friday, September 24, 2021 3:57:07 PM

Post# of 252504
PFE gains royalty on MRK’s Vaxneuvance/V114 pneumococcal vaccine:

https://www.fiercepharma.com/vaccines/pfizer-merck-settle-patent-dispute-next-gen-pneumococcal-shots

In a settlement this week in the U.S. federal court in Delaware, Merck and Pfizer agreed to dismiss patent claims against one another. Under the deal, Merck will pay Pfizer 7.25% of its net sales from pneumococcal conjugate shots worldwide through the end of 2026… After that, the company will owe a 2.5% royalty to its New York rival through the end of 2035…

The royalty is based on the settlement of patent litigation pertaining to conjugated vaccines.

“The efficient-market hypothesis may be
the foremost piece of B.S. ever promulgated
in any area of human knowledge!”

Public Reply Private Reply New Post
Keep Last Read
Keep Last Read Next 10 Report Keyboard Shortcuts
Next 10 Prev Next

Join the InvestorsHub Community

Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.

Sign Up